title: Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA), while decreasing in overall incidence, is still a prominent concern world-wide. New agents coming to market in the last 10 years allow practitioners to optimize treatment for MRSA infections. Ceftobiprole is a cephalosporin agent with MRSA activity, currently approved in selected countries for the treatment of community-acquired pneumonia and hospital-acquired pneumonia. Areas covered: Relevant literature regarding spectrum of activity, pharmacokinetics, pharmacodynamics, and clinical trials will be discussed. Expert opinion: Ceftobiprole is an addition to a growing number of antimicrobials with activity against MRSA. Concern for appropriate dosing in critically ill patients remains due to its ineffectiveness for the treatment of ventilator-associated pneumonia (VAP). While ceftobiprole has activity against gram-negative organisms, the allowance for use of an additional agent for gram-negative infections in clinical trials limits recommendations for monotherapy for empirical treatment of HAP. Ceftobiprole's place in therapy will lie in its activity against gram positive organisms, such as Streptococcus spp. and Staphylococcus spp.
authors.affiliation: a College of Pharmacy , University of Illinois at Chicago , Chicago , IL , USA.
authors.forename: Karolyn S
authors.initials: KS
authors.lastname: Horn
authors.affiliation: a College of Pharmacy , University of Illinois at Chicago , Chicago , IL , USA.|b College of Medicine , University of Illinois at Chicago , Chicago , IL , USA.
authors.forename: Larry H
authors.initials: LH
authors.lastname: Danziger
authors.affiliation: a College of Pharmacy , University of Illinois at Chicago , Chicago , IL , USA.|b College of Medicine , University of Illinois at Chicago , Chicago , IL , USA.
authors.forename: Keith A
authors.initials: KA
authors.lastname: Rodvold
authors.affiliation: a College of Pharmacy , University of Illinois at Chicago , Chicago , IL , USA.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Glowacki
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D016638:Critical Illness; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole
keywords: Methicillin-resistant Staphylococcus aureus; ceftobiprole; community-acquired bacterial pneumonia; hospital-acquired pneumonia